Wire · opportunities
Adjuvant Pembrolizumab Sustains DFS Benefit in Resected NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Adjuvant pembrolizumab continues to extend disease-free survival (DFS) in patients with resected stage IB to IIIA non–small cell lung cancer (NSCLC), but shows no improvement in overall survival (OS), based on the final analysis of the PEARLS/KEYNOTE-091 phase 3 trial. The FDA already approved pembrolizumab in January 2023 for adjuvant treatment post-surgery and platinum chemotherapy in this patient group.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Immunotherapy founders in lung cancer must prepare for heightened use of pembrolizumab as a standard adjuvant treatment driving adoption despite no survival gain. Expect further innovation chances in combination or next-gen therapies to tackle overall survival.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics